Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KRYS Krystal Biotech Inc.

Post-Mkt 10-14 16:49:32 EDT

330.69

+9.53

+2.97%

盘后324.24

-6.45-1.95%

16:34 EDT

High330.97	Low319.01	Vol276.23K
Open320.41	D1 Closing321.16	Amplitude3.72%
Mkt Cap9.79B	Tradable Cap7.78B	Total Shares29.60M
T/O90.70M	T/O Rate1.17%	Tradable Shares23.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KRYS","market":"US","secType":"STK","nameCN":"Krystal Biotech Inc.","latestPrice":330.69,"timestamp":1792008000000,"preClose":321.16,"halted":0,"volume":276229,"hourTrading":{"tag":"盘后","latestPrice":324.24,"preClose":330.69,"latestTime":"16:34 EDT","volume":14445,"amount":4776664.5108,"timestamp":1792010063828,"change":-6.45,"changeRate":-0.019505,"amplitude":0.019505},"delay":0,"changeRate":0.029673682899489264,"floatShares":23539300,"shares":29598836,"eps":7.965707,"marketStatus":"Post-Mkt","change":9.53,"latestTime":"10-14 16:49:32 EDT","open":320.41,"high":330.965,"low":319.01,"amount":90704322.3056,"amplitude":0.037224,"askPrice":336.75,"askSize":16,"bidPrice":324.24,"bidSize":6,"shortable":3,"etf":0,"ttmEps":7.965707,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792022400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":321.16,"preHourTrading":{"tag":"盘前","latestPrice":320.01,"preClose":321.16,"latestTime":"09:29 EDT","volume":87,"amount":27883.921949999996,"timestamp":1791984599984,"change":-1.15,"changeRate":-0.003581,"amplitude":0.038025},"postHourTrading":{"tag":"盘后","latestPrice":324.24,"preClose":330.69,"latestTime":"16:34 EDT","volume":14445,"amount":4776664.5108,"timestamp":1792010063828,"change":-6.45,"changeRate":-0.019505,"amplitude":0.019505},"volumeRatio":1.085839,"impliedVol":0.5252,"impliedVolPercentile":0.8088},"requestUrl":"/m/hq/s/KRYS/wiki","defaultTab":"wiki","newsList":[{"id":"2674076210","title":"What Krystal Biotech (KRYS)'s VYJUVEK Sales Strength Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2674076210","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674076210?lang=en_us&edition=fundamental","pubTime":"2026-10-09 02:29","pubTimestamp":1791484147,"startTime":"0","endTime":"0","summary":"Krystal Biotech has built VYJUVEK into a gene therapy for dystrophic epidermolysis bullosa, generating revenue and gross margins from a recurring treatment model supported by in house manufacturing.\nThe business now leans heavily on VYJUVEK as a rare disease franchise, providing Krystal Biotech with cash flow but also concentrating risk while it works to expand its HSV 1 platform into new indications.\nWe will now see how Krystal Biotech's investment narrative could be shaped by VYJUVEK's...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/what-krystal-biotech-kryss-vyjuvek-sales-strength-means-for","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/what-krystal-biotech-kryss-vyjuvek-sales-strength-means-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XBI","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669631544","title":"Goldman Sachs Resumes Coverage with a Buy Rating on Krystal Biotech (KRYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669631544","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669631544?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:35","pubTimestamp":1790238929,"startTime":"0","endTime":"0","summary":"In a report released today, Andrea Newkirk from Goldman Sachs resumed coverage with a Buy rating on Krystal Biotech and a price target of $441.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-resumes-coverage-with-a-buy-rating-on-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-resumes-coverage-with-a-buy-rating-on-krystal-biotech-krys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928167","title":"S&P 500 Futures Rise in Premarket Trading; Xenon Pharmaceuticals, Icon PLC Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928167?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:30","pubTimestamp":1789731000,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Barrons.com using technology from Automated Insights.With U.S. stock markets set to open in two hours, OceanaGold Corp. (OGC) was up 4.6% in pre-market trad","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYM","VSL","SSS","HELO","XPAY","UXJA","UXJL","LGH","SPY","FEBT","UOCT","BKLC","ISSXF","CPST","LGDX","XXX","VOO","GSUS","KRYS","FLCC","UXAP","VOOG","SPDF","ICLR","PBJL","GBXB","TOPC","PTL","TSPA","VOOX","FELC","DSPY","SPYM","PTLC",".SPX","ABIG","SCHG","MRCP","GPIX","XENE","ACLC","CGUS","VUG","XSPI","CFO","FLAO","OALC","HJUN","BMNR","XUSP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352961","title":"Krystal Biotech CEO Krish S. Krishnan Sells USD 7.59 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352961","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352961?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:15","pubTimestamp":1788563709,"startTime":"0","endTime":"0","summary":"Krystal Biotech CEO Krish S. Krishnan sells USD 7.59 million in common sharesKrish S. Krishnan, president, CEO, director, sold 25,000 Krystal Biotech common shares on Sept. 4, 2026.Sales prices cluste","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL3bqQgC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech CEO Krish S. Krishnan Sells USD 7.59 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PSCH","BK4139","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871013","title":"Krystal Biotech to Speak at Cantor Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871013","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664871013?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:07","pubTimestamp":1788437263,"startTime":"0","endTime":"0","summary":"Krystal Biotech to speak at Cantor Global Healthcare Conference fireside chatKrystal Biotech will participate in the 2026 Cantor Global Healthcare Conference on Sept. 10, 2026, in New York.Management ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL65Fmjd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","SG9999014005.SGD","BK4139","IE00BQXX3D17.EUR","HELX","LU2210149790.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BCDF","LU2210150020.SGD","BK4585","IE00BQXX3C00.GBP","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","BK4112","IE00BGHQF748.EUR","BK4588","NDAQ","PSCH","SG9999014021.USD","IE00BN0W2V16.EUR","KRYS","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661652248","title":"Krystal Biotech (KRYS) Rallies On Pipeline Hopes But Is The Valuation Already Priced In","url":"https://stock-news.laohu8.com/highlight/detail?id=2661652248","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661652248?lang=en_us&edition=fundamental","pubTime":"2026-08-23 17:16","pubTimestamp":1787476617,"startTime":"0","endTime":"0","summary":"Krystal Biotech stock performance snapshot\nKrystal Biotech (KRYS) has attracted fresh attention after recent share price gains, with the stock closing at $346.58 on 19 August 2026. Investors are weighing these moves against its recent return profile and fundamentals.\nOver the past month the stock shows a 3.4% return, with about 15.7% in the past 3 months and 40.4% year to date. Its 1 year total return is 130.3%, while the 3 year figure is approximately 1.7 times and the 5 year total return is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-rallies-on-pipeline-hopes-but-is-the-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-rallies-on-pipeline-hopes-but-is-the-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PSCH","BK4139","BK4581","BK4585","KRYS","BK4588","HELX","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659817185","title":"Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?","url":"https://stock-news.laohu8.com/highlight/detail?id=2659817185","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659817185?lang=en_us&edition=fundamental","pubTime":"2026-08-16 09:22","pubTimestamp":1786843346,"startTime":"0","endTime":"0","summary":"In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a year earlier.\nOver the first half of 2026, net income rose to US$110.70 million and higher per-share earnings underscored the earnings power of Vyjuvek alongside an advancing gene therapy pipeline.\nWe’ll now examine how this stronger profitability profile, anchored by Vyjuvek’s contribution,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KRYS","ISBC","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659124086","title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2659124086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659124086?lang=en_us&edition=fundamental","pubTime":"2026-08-15 06:23","pubTimestamp":1786746202,"startTime":"0","endTime":"0","summary":"Krystal Biotech Director Dino A. Rossi disposes of USD 8.17 million in common sharesDirector Dino A. Rossi cut his Krystal Biotech stake to 50,000 shares on Aug. 14, 2026.Disposed of 25,000 common sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL6DCXXB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech Director Dino A. Rossi Disposes of USD 8.17 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","BK4139","KRYS","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659140246","title":"Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659140246","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659140246?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:11","pubTimestamp":1786720282,"startTime":"0","endTime":"0","summary":"Krystal Biotech  has further room for gains driven by Vyjuvek, its treatment for the rare blistering condition dystrophic epidermolysis bullosa, alongside international launches and growth across its gene therapy pipeline, RBC Capital said Friday in a report.Krystal's neurotrophic keratitis program could be its next major catalyst, with pivotal data expected in early 2027, RBC said. Shares may rise 30% if results match the current standard of care, while a weak outcome might prompt a 15% decline, the report said.RBC forecasts peak NK sales of $2.1 billion in 2030, citing the established market and potential for the therapy to become a best-in-class treatment, though the outlook remains \"cautiously optimistic\" given limited clinical data.Vyjuvek holds more than 60% of the US market, while international launches are expected to drive the next phase of growth, the report said. RBC projects Vyjuvek peak sales of $1 billion by 2033 and pointed to H2 readouts in ocular DEB, cystic fibrosis a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4581","PSCH","HELX","XBI","BK4139","BK4585","BK4588","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659414194","title":"Krystal Biotech (KRYS) Has a New Rating from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2659414194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659414194?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:38","pubTimestamp":1786711085,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Lisa Walter initiated coverage with a Buy rating on Krystal Biotech today and set a price target of $400.00. According to TipRa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/krystal-biotech-krys-has-a-new-rating-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/krystal-biotech-krys-has-a-new-rating-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRYS","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659428117","title":"Krystal Biotech, Inc. : RBC Initiates Coverage with Outperform Rating; Target Price $400","url":"https://stock-news.laohu8.com/highlight/detail?id=2659428117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659428117?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:39","pubTimestamp":1786700394,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nFWN44B0NL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KRYS","BK4139","PSCH","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659918429","title":"Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2659918429","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659918429?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:37","pubTimestamp":1786581477,"startTime":"0","endTime":"0","summary":"Krystal Biotech earnings and revenue momentum come into focus\nKrystal Biotech (KRYS) is back in the spotlight after reporting second quarter 2026 results that included net income of US$54.77 million and basic earnings per share from continuing operations of US$1.85.\nSee our latest analysis for Krystal Biotech.\nThe recent earnings update and 24% net product revenue growth for VYJUVEK came after a strong run, with Krystal Biotech posting a year to date share price return of 34.81% and a 1 year...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-earnings-and-pipeline-progress-put-valu","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/krystal-biotech-krys-earnings-and-pipeline-progress-put-valu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KRYS","XBI","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657208075","title":"Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657208075","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657208075?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:08","pubTimestamp":1785960518,"startTime":"0","endTime":"0","summary":"Arcutis Q2 revenue rises on demand for ZORYVE, lifts 2026 sales outlookOverviewUS dermatology drug maker's Q2 product revenue rose 59% yr/yr, driven by ZORYVE demandCompany raised 2026 full-year net p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","PSCH","KRYS","ACAD","LU2065170008.USD","LU2065171402.SGD","SNDX","BK4139","ARQT","LU2065169927.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543991","title":"United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543991","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543991?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:38","pubTimestamp":1785926324,"startTime":"0","endTime":"0","summary":"United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weaknessOverviewRare disease drugmaker's Q2 revenue fell 2% yr/yr, missing analyst expectationsQ2 net income rose 8% yr/yr; diluted E","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","LU1571399168.USD","TVTX","PSCH","BK4139","LFSC","BK4532","UTHR","LU1699723380.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657404561","title":"Ultragenyx Q2 Revenue Rises 28% to Record High, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657404561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657404561?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:18","pubTimestamp":1785874711,"startTime":"0","endTime":"0","summary":"Ultragenyx Q2 revenue rises 28% to record high, net loss narrowsOverviewUS biopharma for rare diseases reported Q2 revenue up yr/yr to highest in company historyNet loss for Q2 narrowed yr/yr, with lo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nL1N441167:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","RARE","HELX","BK4585","BK4588","RYTM","BK4139","HRMY","BK4007","KRYS","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156455734","title":"Movement Alert｜Krystal Biotech Inc. Rises 5.04% in Regular Trading, Q2 Earnings Beat Drives Oversold Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1156455734","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156455734?lang=en_us&edition=fundamental","pubTime":"2026-08-05 03:41","pubTimestamp":1785872506,"startTime":"0","endTime":"0","summary":"On August 4, Krystal Biotech Inc. rose 5.04% in regular trading, trading at approximately $328.31/share, with turnover of $119 million. The rebound follows a sharp sell-off of over 9% in the prior...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656083301","title":"ClearPoint Neuro Q2 Revenue Rises 18% but Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656083301","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656083301?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:14","pubTimestamp":1785788065,"startTime":"0","endTime":"0","summary":"ClearPoint Neuro Q2 revenue rises 18% but misses estimatesOverviewDevice and gene therapy-enabling firm's Q2 revenue rose 18% yr/yr but missed analyst expectationsGross margin improved to 62% from 60%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400ZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLPT","BK4082","KRYS","PSCH","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656301205","title":"GeneDx Q2 Revenue Beats Analyst Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2656301205","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656301205?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:12","pubTimestamp":1785787943,"startTime":"0","endTime":"0","summary":"GeneDx Q2 revenue beats analyst estimatesOverviewU.S. rare disease genomics tester's Q2 revenue grew 11% yr/yr, beating analyst expectationsAdjusted net income was $0.4 mln, up from a loss in the prio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WGS","PSCH","BK4196","KRYS","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656303023","title":"Krystal Biotech Down Nearly 12%, on Pace for Largest Percent Decrease Since August 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2656303023","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656303023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 01:25","pubTimestamp":1785777900,"startTime":"0","endTime":"0","summary":"Krystal Biotech, Inc.  is currently at $300.76, down $40.37 or 11.83%--Would be lowest close since June 2, 2026, when it closed at $293.21--On pace for largest percent decrease since Aug. 4, 2025, when it fell 14.04%--Currently down three of the past four days--Currently down two consecutive days; down 18.02% over this period--Worst two day stretch since the two days ending May 9, 2022, when it fell 21.35%--Up 21.99% year-to-date--Down 20.47% from its all-time closing high of $378.15 on June 29, 2026--Up 122.88% from 52 weeks ago , when it closed at $134.94--Down 20.47% from its 52-week closing high of $378.15 on June 29, 2026--Up 122.88% from its 52-week closing low of $134.94 on Aug. 4, 2025--Traded as low as $297.02; lowest intraday level since June 3, 2026, when it hit $290.04--Down 12.93% at today's intraday low; largest intraday percent decrease since Aug. 4, 2025, when it fell as much as 16.87%All data as of 1:20:00 PM ETSource: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PSCH","BK4585","BK4139","XBI","BK4581","BK4588","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330819","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656330819?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:00","pubTimestamp":1785772852,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD) and Krystal Biotech (KRYS) with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-271?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KRYS","IRD","HELX","BK4139","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.krystalbio.com","stockEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.0745},{"period":"3month","weight":-0.083},{"period":"6month","weight":0.2162},{"period":"1year","weight":0.7384},{"period":"ytd","weight":0.3027}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0307},{"period":"6month","weight":0.1088},{"period":"1year","weight":0.1734},{"period":"ytd","weight":0.1409}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.012037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.08189},{"month":3,"riseRate":0.555556,"avgChangeRate":0.037905},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.016835},{"month":5,"riseRate":0.555556,"avgChangeRate":0.031146},{"month":6,"riseRate":0.777778,"avgChangeRate":0.125274},{"month":7,"riseRate":0.666667,"avgChangeRate":0.059124},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.003821},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.041988},{"month":10,"riseRate":0.5,"avgChangeRate":0.04435},{"month":11,"riseRate":0.888889,"avgChangeRate":0.190014},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.011676}],"exchange":"NASDAQ","name":"Krystal Biotech Inc.","nameEN":"Krystal Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Krystal Biotech Inc.(KRYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Krystal Biotech Inc.,KRYS,Krystal Biotech Inc.股票,Krystal Biotech Inc.股票老虎,Krystal Biotech Inc.股票老虎国际,Krystal Biotech Inc.行情,Krystal Biotech Inc.股票行情,Krystal Biotech Inc.股价,Krystal Biotech Inc.股市,Krystal Biotech Inc.股票价格,Krystal Biotech Inc.股票交易,Krystal Biotech Inc.股票购买,Krystal Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Krystal Biotech Inc.(KRYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Krystal Biotech Inc.(KRYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}